Within-host co-evolution of Gag P453L and protease D30N/N88D demonstrates virological advantage in a highly protease inhibitor-exposed HIV-1 case

Antiviral Research

Volumn 90, Issue 1, 2011, Pages 33-41

  Shibata, Junko ^a,b,f   Sugiura, Wataru ^b,c,d   Ode, Hirotaka ^d   Iwatani, Yasumasa ^b,c,d   Sato, Hironori ^d   Tsang, Hsinyi ^b   Matsuda, Masakazu ^d,e   Hasegawa, Naoki ^a   Ren, Fengrong ^a   Tanaka, Hiroshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^e LSI MEDIENCE CORPORATION   (Japan)

^f INSERM   (France)

Author keywords

Co evolution; Drug resistance; Gag; HIV; Protease

Indexed keywords

GAG PROTEIN; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR;

AIDS PATIENT; ARTICLE; BIOINFORMATICS; CASE REPORT; GENE MUTATION; GENE REPLICATION; GENE SEQUENCE; HAPLORHINI; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYDROGEN BOND; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SEQUENCE HOMOLOGY; VIROLOGY;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION, MISSENSE; SELECTION, GENETIC; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79953675052     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.02.004     Document Type: Article

References (55)

1. Altschuh D., Lesk A.M., Bloomer A.C., Klug A. Correlation of co-ordinated amino acid substitutions with function in viruses related to tobacco mosaic virus. J. Mol. Biol. 1987, 193:693-707.
2. Baker D., Sali A. Protein structure prediction and structural genomics. Science 2001, 294:93-96.
3. Bally F., Martinez R., Peters S., Sudre P., Telenti A. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res. Hum. Retroviruses 2000, 16:1209-1213.
4. Bhattacharya T., Daniels M., Heckerman D., Foley B., Frahm N., Kadie C., Carlson J., Yusim K., McMahon B., Gaschen B., Mallal S., Mullins J.I., Nickle D.C., Herbeck J., Rousseau C., Learn G.H., Miura T., Brander C., Walker B., Korber B. Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 2007, 315:1583-1586.
5. Brumme Z.L., John M., Carlson J.M., Brumme C.J., Chan D., Brockman M.A., Swenson L.C., Tao I., Szeto S., Rosato P., Sela J., Kadie C.M., Frahm N., Brander C., Haas D.W., Riddler S.A., Haubrich R., Walker B.D., Harrigan P.R., Heckerman D., Mallal S. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One 2009, 4:e6687.
6. Chiba-Mizutani T., Miura H., Matsuda M., Matsuda Z., Yokomaku Y., Miyauchi K., Nishizawa M., Yamamoto N., Sugiura W. Use of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to anti-human immunodeficiency virus type 1 drugs. J. Clin. Microbiol. 2007, 45:477-487.
7. Dam E., Quercia R., Glass B., Descamps D., Launay O., Duval X., Krausslich H.G., Hance A.J., Clavel F. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog. 2009, 5:e1000345.
8. Doyon L., Croteau G., Thibeault D., Poulin F., Pilote L., Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 1996, 70:3763-3769.
9. Dutheil J., Pupko T., Jean-Marie A., Galtier N. A model-based approach for detecting coevolving positions in a molecule. Mol. Biol. Evol. 2005, 22:1919-1928.
10. Gallego O., de Mendoza C., Corral A., Soriano V. Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients. J. Clin. Microbiol. 2003, 41:1245-1247.
11. Gunthard H.F., Wong J.K., Ignacio C.C., Havlir D.V., Richman D.D. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res. Hum. Retroviruses 1998, 14:869-876.
12. Gutell R.R., Power A., Hertz G.Z., Putz E.J., Stormo G.D. Identifying constraints on the higher-order structure of RNA: continued development and application of comparative sequence analysis methods. Nucleic Acids Res. 1992, 20:5785-5795.
13. Hance A.J., Lemiale V., Izopet J., Lecossier D., Joly V., Massip P., Mammano F., Descamps D., Brun-Vézinet F., Clavel F. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J. Virol. 2001, 75:6410-6417.
14. Ho S.K., Coman R.M., Bunger J.C., Rose S.L., O'Brien P., Munoz I., Dunn B.M., Sleasman J.W., Goodenow M.M. Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. Virology 2008.
15. Johnson V.A., Brun-Vézinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., Schapiro J.M., Richman D.D. Update of the drug resistance mutations in HIV-1: Spring 2008. Top. HIV Med. 2008, 16:62-68.
16. Johnson V.A., Brun-Vézinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., Schapiro J.M., Richman D.D. Update of the drug resistance mutations in HIV-1: December 2009. Top. HIV Med. 2009, 17:138-145.
17. Koch N., Yahi N., Fantini J., Tamalet C. Mutations in HIV-1 gag cleavage sites and their association with protease mutations. AIDS 2001, 15:526-528.
18. Kolli M., Lastere S., Schiffer C.A. Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate. Virology 2006, 347:405-409.
19. Kolli M., Stawiski E., Chappey C., Schiffer C.A. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance. J. Virol. 2009, 83:11027-11042.
20. Labute P. The generalized Born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J. Comput. Chem. 2008, 29:1693-1698.
21. Maguire M.F., Guinea R., Griffin P., Macmanus S., Elston R.C., Wolfram J., Richards N., Hanlon M.H., Porter D.J., Wrin T., Parkin N., Tisdale M., Furfine E., Petropoulos C., Snowden B.W., Kleim J.P. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J. Virol. 2002, 76:7398-7406.
22. Mahalingam B., Louis J.M., Reed C.C., Adomat J.M., Krouse J., Wang Y.F., Harrison R.W., Weber I.T. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Eur. J. Biochem. 1999, 263:238-245.
23. Malet I., Roquebert B., Dalban C., Wirden M., Amellal B., Agher R., Simon A., Katlama C., Costagliola D., Calvez V., Marcelin A.G. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. J. Infect. 2007, 54:367-374.
24. Marti-Renom M.A., Stuart A.C., Fiser A., Sanchez R., Melo F., Sali A. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 2000, 29:291-325.
25. Martin L.C., Gloor G.B., Dunn S.D., Wahl L.M. Using information theory to search for co-evolving residues in proteins. Bioinformatics 2005, 21:4116-4124.
26. Martinez-Picado J., Savara A.V., Sutton L., D'Aquila R.T. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 1999, 73:3744-3752.
27. Matsuoka-Aizawa S., Sato H., Hachiya A., Tsuchiya K., Takebe Y., Gatanaga H., Kimura S., Oka S. Isolation and molecular characterization of a nelfinavir (NFV)-resistant human immunodeficiency virus type 1 that exhibits NFV-dependent enhancement of replication. J. Virol. 2003, 77:318-327.
28. Meyerhans A., Vartanian J.P., Wain-Hobson S. DNA recombination during PCR. Nucleic Acids Res. 1990, 18:1687-1691.
29. Mitsuya Y., Winters M.A., Fessel W.J., Rhee S.Y., Hurley L., Horberg M., Schiffer C.A., Zolopa A.R., Shafer R.W. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. AIDS Res. Hum. Retroviruses 2006, 22:1300-1305.
30. Myint L., Matsuda M., Matsuda Z., Yokomaku Y., Chiba T., Okano A., Yamada K., Sugiura W. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2004, 48:444-452.
31. Neher E. How frequent are correlated changes in families of protein sequences?. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:98-102.
32. Nickle D.C., Heath L., Jensen M.A., Gilbert P.B., Mullins J.I., Kosakovsky Pond S.L. HIV-specific probabilistic models of protein evolution. PLoS One 2007, 2:e503.
33. Nijhuis M., Schuurman R., de Jong D., Erickson J., Gustchina E., Albert J., Schipper P., Gulnik S., Boucher C.A. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999, 13:2349-2359.
34. Palmer S., Kearney M., Maldarelli F., Halvas E.K., Bixby C.J., Bazmi H., Rock D., Falloon J., Davey R.T., Dewar R.L., Metcalf J.A., Hammer S., Mellors J.W., Coffin J.M. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 2005, 43:406-413.
35. Pollock D.D., Taylor W.R. Effectiveness of correlation analysis in identifying protein residues undergoing correlated evolution. Protein Eng. 1997, 10:647-657.
36. Poon A.F., Kosakovsky Pond S.L., Richman D.D., Frost S.D. Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients. J. Virol. 2007, 81:13598-13607.
37. Poon A.F., Lewis F.I., Frost S.D., Pond S.L. Spidermonkey: rapid detection of co-evolving sites using Bayesian graphical models. Bioinformatics 2008.
38. Poon A.F., Lewis F.I., Pond S.L., Frost S.D. An evolutionary-network model reveals stratified interactions in the V3 loop of the HIV-1 envelope. PLoS Comput. Biol. 2007, 3:e231.
39. Prabu-Jeyabalan M., Nalivaika E., Schiffer C.A. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 2002, 10:369-381.
40. Prabu-Jeyabalan M., Nalivaika E.A., King N.M., Schiffer C.A. Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J Virol 2004, 78:12446-12454.
41. Rhee S.Y., Liu T.F., Holmes S.P., Shafer R.W. HIV-1 subtype B protease and reverse transcriptase amino acid covariation. PLoS Comput. Biol. 2007, 3:e87.
42. Saitou N., Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 1987, 4:406-425.
43. Sayer J.M., Liu F., Ishima R., Weber I.T., Louis J.M. Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease. J. Biol. Chem. 2008, 283:13459-13470.
44. Shirakawa K., Takaori-Kondo A., Yokoyama M., Izumi T., Matsui M., Io K., Sato T., Sato H., Uchiyama T. Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif. Nat. Struct. Mol. Biol. 2008, 15:1184-1191.
45. Sugiura W., Matsuda Z., Yokomaku Y., Hertogs K., Larder B., Oishi T., Okano A., Shiino T., Tatsumi M., Matsuda M., Abumi H., Takata N., Shirahata S., Yamada K., Yoshikura H., Nagai Y. Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2002, 46:708-715.
46. Tillier E.R., Lui T.W. Using multiple interdependency to separate functional from phylogenetic correlations in protein alignments. Bioinformatics 2003, 19:750-755.
47. Tuff P., Darlu P. Exploring a phylogenetic approach for the detection of correlated substitutions in proteins. Mol. Biol. Evol. 2000, 17:1753-1759.
48. Verheyen J., Litau E., Sing T., Daumer M., Balduin M., Oette M., Fatkenheuer G., Rockstroh J.K., Schuldenzucker U., Hoffmann D., Pfister H., Kaiser R. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir. Ther. 2006, 11:879-887.
49. von Schwedler U.K., Stuchell M., Muller B., Ward D.M., Chung H.Y., Morita E., Wang H.E., Davis T., He G.P., Cimbora D.M., Scott A., Krausslich H.G., Kaplan J., Morham S.G., Sundquist W.I. The protein network of HIV budding. Cell 2003, 114:701-713.
50. Wang J., Cieplak P., Kollman P.A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules?. Journal of Computational Chemistry 2000, 21:1049-1074.
51. Willey R.L., Smith D.H., Lasky L.A., Theodore T.S., Earl P.L., Moss B., Capon D.J., Martin M.A. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J. Virol. 1988, 62:139-147.
52. Wollenberg K.R., Atchley W.R. Separation of phylogenetic and functional associations in biological sequences by using the parametric bootstrap. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3288-3291.
53. Wu T.D., Schiffer C.A., Gonzales M.J., Taylor J., Kantor R., Chou S., Israelski D., Zolopa A.R., Fessel W.J., Shafer R.W. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J. Virol. 2003, 77:4836-4847.
54. Yeang C.H., Haussler D. Detecting coevolution in and among protein domains. PLoS Comput. Biol. 2007, 3:e211.
55. Zhang Y.M., Imamichi H., Imamichi T., Lane H.C., Falloon J., Vasudevachari M.B., Salzman N.P. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 1997, 71:6662-6670.